Hemoglobin Variability and Mortality in ESRD

Wei Yang,* Rubeen K. Israni,*† Steven M. Brunelli,*† Marshall M. Joffe,* Steven Fishbane,‡ and Harold I. Feldman*†

*Center for Clinical Epidemiology and Biostatistics and the Department of Biostatistics and Epidemiology, and the 
†Renal Electrolyte and Hypertension Division of the Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania; ‡Winthrop University Hospital, Mineola, New York

ABSTRACT

Hemoglobin levels vary substantially over time in hemodialysis patients, and this variability may portend poor outcomes. For a given patient, hemoglobin concentration over time can be described by absolute levels, rate of change, or by the difference between observed level and expected level based on the preceding trend (i.e., seemingly random variability). We investigated the independent associations of these different methods of describing hemoglobin over time with mortality in a retrospective cohort of 34,963 hemodialysis patients. Hemoglobin concentration over time was modeled with linear regression for each subject, and the model was then used to define the subject’s absolute level of hemoglobin (intercept), temporal trend in hemoglobin (slope), and hemoglobin variability (residual standard deviation). Survival analyses indicated that each 1 g/dl increase in the residual standard deviation was associated with a 33% increase in rate of death, even after adjusting for multiple covariates. Patient characteristics accounted for very little of the variation in our hemoglobin variability metric ($R^2 = 0.019$). We conclude that greater hemoglobin variability is independently associated with higher mortality.


Widespread use of erythropoiesis-stimulating agents and intravenous iron has revolutionized anemia management in ESRD. Over the past 15 yr, average hemoglobin levels have increased from <10 g/dl to >12 g/dl among chronic dialysis patients.1 However, these higher levels of hemoglobin have not necessarily translated into improved patient outcomes.

Multiple studies suggest an association between higher hemoglobin level and improved quality of life, physical function, and exercise capacity,2–5 but the association with survival is less clear. Whereas observational studies have generally shown increased survival with higher hemoglobin levels,6–9 randomized trials have not shown such benefits.10–12 Moreover, some randomized trials have suggested an increase in cardiovascular events associated with higher hemoglobin levels among hemodialysis patients.5–8 and chronic kidney disease patients.11,12 The evidence from randomized trials is especially significant in light of a recent report showing that for-profit dialysis chains administer higher epoetin doses even when hemoglobin is within the 11 to 12 g/dl range, and have a higher proportion of patients with hemoglobin >12 g/dl.13,14

Preliminary evidence suggests the effects of hemoglobin on clinical outcomes may not be captured by the absolute level of hemoglobin alone. Measures of their change over time have also been associated with adverse patient outcomes.15,16 Such changes may take the form of temporal trends or random variability about this trend (henceforth referred to as hemoglobin variability or Hb-Var). Prior studies examining the association between hemoglobin levels and out-
comes have not fully distinguished among absolute hemoglobin level, temporal trend, and Hb-Var. This may have contributed to inconsistent findings across studies, and made it difficult to determine the independent relationship between each of these aspects of hemoglobin management and outcome.16–20

To better elucidate the independent association between Hb-Var and outcome, we have developed a new, regression-based metric of Hb-Var that simultaneously describes and distinguishes among variability, absolute level of, and temporal trend in longitudinal hemoglobin levels (Figure 1a). Using a historical national cohort of prevalent hemodialysis patients, we compare this regression-based measure of Hb-Var to an alternative formulation (the average absolute change; Figure 1b),21 explore clinical predictors of high levels of Hb-Var, and characterize the association between Hb-Var and all-cause mortality.

RESULTS

Subject Eligibility and Characteristics
The Fresenius Medical Care (FMC) database included records on 34,963 hemodialysis patients: 30,693 had at least two hemoglobin measurements during the exposure window needed to measure the average absolute change in hemoglobin, and 30,603 had at least three hemoglobin measurements needed to define residual SD. The primary survival analysis considered the 19,150 subjects who remained enrolled throughout the hemoglobin exposure window and had no missing hemoglobin or covariates values over that period; 8797, 5246, and 2523 subjects qualified for sensitivity analyses that further restricted consideration to subjects with minimum hemoglobin

Table 1. Baseline demographic characteristics, laboratory and treatment-related measures in the cohort

<table>
<thead>
<tr>
<th>Measure</th>
<th>Mean ± SD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, yr (mean ± SD)</td>
<td>60.1 ± 15.1</td>
</tr>
<tr>
<td>Duration of ESRD, yr (mean ± SD)</td>
<td>3.6 ± 3.6</td>
</tr>
<tr>
<td>Gender</td>
<td></td>
</tr>
<tr>
<td>male, %</td>
<td>50.6</td>
</tr>
<tr>
<td>female, %</td>
<td>49.4</td>
</tr>
<tr>
<td>Race</td>
<td></td>
</tr>
<tr>
<td>white</td>
<td>48.9</td>
</tr>
<tr>
<td>black</td>
<td>44.7</td>
</tr>
<tr>
<td>Native American</td>
<td>0.7</td>
</tr>
<tr>
<td>Asian/Pacific Islander</td>
<td>1.6</td>
</tr>
<tr>
<td>other</td>
<td>4.2</td>
</tr>
<tr>
<td>Diabetes mellitus, %</td>
<td></td>
</tr>
<tr>
<td>adult onset</td>
<td>40.5</td>
</tr>
<tr>
<td>juvenile onset</td>
<td>4.5</td>
</tr>
<tr>
<td>none</td>
<td>55</td>
</tr>
<tr>
<td>Laboratory measures at 3 mo (mean ± SD)</td>
<td></td>
</tr>
<tr>
<td>hemoglobin, g/dl</td>
<td>10.2 ± 1.2</td>
</tr>
<tr>
<td>urea reduction ratio, %</td>
<td>67.3 ± 7.0</td>
</tr>
<tr>
<td>Kt/V</td>
<td>1.4 ± 0.2</td>
</tr>
<tr>
<td>albumin, g/dl</td>
<td>3.9 ± 0.4</td>
</tr>
<tr>
<td>bicarbonate, mEq/L</td>
<td>20.6 ± 3.0</td>
</tr>
<tr>
<td>aspartate aminotransferase, IU/L</td>
<td>19 ± 15.5</td>
</tr>
<tr>
<td>calcium, mg/dl</td>
<td>9.0 ± 0.8</td>
</tr>
<tr>
<td>phosphate, mg/dl</td>
<td>6.0 ± 1.7</td>
</tr>
<tr>
<td>intact PTH, pg/ml</td>
<td>315 ± 433</td>
</tr>
<tr>
<td>ferritin, ng/ml</td>
<td>352 ± 402</td>
</tr>
<tr>
<td>transferrin saturation, %</td>
<td>26.7 ± 11.6</td>
</tr>
<tr>
<td>iron level, μg/dl</td>
<td>57.2 ± 24.3</td>
</tr>
<tr>
<td>Treatment measures (mean ± SD)</td>
<td></td>
</tr>
<tr>
<td>intravenous iron dose summed over 3 mo, mg</td>
<td>944 ± 546</td>
</tr>
<tr>
<td>erythropoietin dose average over 3 mo, U</td>
<td>50,875 ± 32,238</td>
</tr>
</tbody>
</table>

N = 34,963 patients.

To better elucidate the independent association between Hb-Var and outcome, we have developed a new, regression-based metric of Hb-Var that simultaneously describes and distinguishes among variability, absolute level of, and temporal trend in longitudinal hemoglobin levels (Figure 1a). Using a historical national cohort of prevalent hemodialysis patients, we compare this regression-based measure of Hb-Var to an alternative formulation (the average absolute change; Figure 1b),21 explore clinical predictors of high levels of Hb-Var, and characterize the association between Hb-Var and all-cause mortality.

Table 1. Baseline demographic characteristics, laboratory and treatment-related measures in the cohort

<table>
<thead>
<tr>
<th>Measure</th>
<th>Mean ± SD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, yr (mean ± SD)</td>
<td>60.1 ± 15.1</td>
</tr>
<tr>
<td>Duration of ESRD, yr (mean ± SD)</td>
<td>3.6 ± 3.6</td>
</tr>
<tr>
<td>Gender</td>
<td></td>
</tr>
<tr>
<td>male, %</td>
<td>50.6</td>
</tr>
<tr>
<td>female, %</td>
<td>49.4</td>
</tr>
<tr>
<td>Race</td>
<td></td>
</tr>
<tr>
<td>white</td>
<td>48.9</td>
</tr>
<tr>
<td>black</td>
<td>44.7</td>
</tr>
<tr>
<td>Native American</td>
<td>0.7</td>
</tr>
<tr>
<td>Asian/Pacific Islander</td>
<td>1.6</td>
</tr>
<tr>
<td>other</td>
<td>4.2</td>
</tr>
<tr>
<td>Diabetes mellitus, %</td>
<td></td>
</tr>
<tr>
<td>adult onset</td>
<td>40.5</td>
</tr>
<tr>
<td>juvenile onset</td>
<td>4.5</td>
</tr>
<tr>
<td>none</td>
<td>55</td>
</tr>
<tr>
<td>Laboratory measures at 3 mo (mean ± SD)</td>
<td></td>
</tr>
<tr>
<td>hemoglobin, g/dl</td>
<td>10.2 ± 1.2</td>
</tr>
<tr>
<td>urea reduction ratio, %</td>
<td>67.3 ± 7.0</td>
</tr>
<tr>
<td>Kt/V</td>
<td>1.4 ± 0.2</td>
</tr>
<tr>
<td>albumin, g/dl</td>
<td>3.9 ± 0.4</td>
</tr>
<tr>
<td>bicarbonate, mEq/L</td>
<td>20.6 ± 3.0</td>
</tr>
<tr>
<td>aspartate aminotransferase, IU/L</td>
<td>19 ± 15.5</td>
</tr>
<tr>
<td>calcium, mg/dl</td>
<td>9.0 ± 0.8</td>
</tr>
<tr>
<td>phosphate, mg/dl</td>
<td>6.0 ± 1.7</td>
</tr>
<tr>
<td>intact PTH, pg/ml</td>
<td>315 ± 433</td>
</tr>
<tr>
<td>ferritin, ng/ml</td>
<td>352 ± 402</td>
</tr>
<tr>
<td>transferrin saturation, %</td>
<td>26.7 ± 11.6</td>
</tr>
<tr>
<td>iron level, μg/dl</td>
<td>57.2 ± 24.3</td>
</tr>
<tr>
<td>Treatment measures (mean ± SD)</td>
<td></td>
</tr>
<tr>
<td>intravenous iron dose summed over 3 mo, mg</td>
<td>944 ± 546</td>
</tr>
<tr>
<td>erythropoietin dose average over 3 mo, U</td>
<td>50,875 ± 32,238</td>
</tr>
</tbody>
</table>

N = 34,963 patients.
the average absolute change and residual SD were highly correlated ($r = 0.91$). There was little correlation between intercept and Hb-Var, as defined as either Res-SD ($r = -0.10$) or average absolute change ($r = -0.08$). These near-zero values indicate that neither metric of Hb-Var was explained well by absolute hemoglobin level.

Both measures of Hb-Var demonstrated low degrees of correlation with temporal hemoglobin trend ($r = 0.01$ and $r = 0.03$, respectively). However, scatter plots of slope versus average absolute change, but not residual SD, demonstrated a conical shape (Figure 3), indicating dependence of average absolute change on temporal hemoglobin trend (i.e., the values of average absolute change could not be small when temporal hemoglobin change was large). Therefore, we chose Res-SD as our primary metric of Hb-Var in subsequent analyses.

The distribution of Res-SD was similar across strata of patients defined by hemoglobin trend: Mean Res-SD was 0.64 g/dl, 0.55 g/dl, and 0.64 g/dl for subjects with slope $<-1$ g/dl per 6 mo, $>-1$ and $<1$ g/dl per 6 mo, $>1$ g/dl per 6 mo (corresponding to what we hypothesized was a meaningful clinical temporal change).

**Prediction of Residual SD of Hemoglobin**

A linear regression model was used to identify potential predictors of increased Hb-Var. Although the variables of age, gender, duration of ESRD, average hemoglobin level, serum albumin, aspartate aminotransferase, calcium, intact parathyroid hormone level, iron level, and erythropoietin dose reached conventional levels of statistical significance (possibly because of a large sample size), the overall $R^2$ for this model was 0.019, demonstrating that these factors, collectively, accounted for very little of observed variation in Hb-Var among subjects.

**Survival Analysis**

Hb-Var was associated with decreased survival after adjusting for known confounders in adjusted proportional hazards analysis. For each 1-g/dl increase in hemoglobin Res-SD, there was a 33% increase in the rate of death (Table 2). As expected, a higher absolute level of hemoglobin and a positive value for temporal trend in hemoglobin were also associated with longer survival. There were no significant interactions between Hb-Var and absolute level of hemoglobin, or between Hb-Var and temporal trend in hemoglobin (data not shown).

**Sensitivity Analyses**

Three subgroups of patients with increasingly restrictive minimum hemoglobin values during the 6-mo hemoglobin exposure windows were examined. For each subgroup, the association between Hb-Var and survival was of the same magnitude and in the same direction as the overall population except for the highest minimum hemoglobin group, for which the confidence intervals were wide (Table 3) because of the small sample size.

Finally, while beyond the scope of this article, we have also assessed the independent association between greater Hb-Var and increased all-cause mortality by fitting history-adjusted marginal structural models as yet another method to control for time-dependent confounding. This analysis yielded nearly identical magnitudes of association between hemoglobin variability and mortality (data not shown).
DISCUSSION

Variability of hemoglobin over time both complicates management of anemia in ESRD, and is potentially associated with increased mortality among dialysis-treated patients. Reported measures of hemoglobin variability have not characterized variability distinct from the temporal trend in hemoglobin.\textsuperscript{15,17–20} We established that the hemoglobin variability, as measured by the residual SD of hemoglobin, was independent of both the absolute level and trend over time in hemoglobin concentration, and was superior in this regard to average absolute change. Although we were unable to identify patient demographic, laboratory, or treatment-related characteristics that explained much of the observed variability in Hb-Var, we demonstrated a strong and independent association between high levels of Hb-Var and greater mortality.

Survival analysis demonstrated a 33\% increase in the adjusted rate of death for each 1-g/dl increase in Hb-Var. Greater Hb-Var was strongly associated with diminished survival, even after multivariable adjustment for absolute level and temporal trend in hemoglobin concentration among ESRD patients receiving chronic hemodialysis. This finding was also consistent within all but one subgroup with restricted minimum levels of hemoglobin, in which the opportunity for residual confounding was less plausible.

The consistency of results across various modeling strategies demonstrating greater hemoglobin variability associated with increased mortality supports the hypothesis that Hb-Var represents an important physiologic stress. Other than in chronic diseases such as ESRD, hemoglobin levels are typically maintained within a narrow range, ensuring consistent tissue oxygen delivery. Repeated episodes of relative ischemia and tissue hypoxia in ESRD may result in organ dysfunction or injury. The myocardium may be particularly vulnerable to hemoglobin variability, as it compensates for periods of reduced oxygen delivery with increased output and myocardial cell growth.\textsuperscript{25} The results may be repeated activation and resetting of cardiac growth signals, and the development of pathologic changes such as left ventricular dilation or hypertrophy.\textsuperscript{26,27} The autonomic nervous system may also be vulnerable to hemoglobin variability, as autonomic dysfunction has been observed in other conditions that predispose patients to fluctuating hemoglobin levels, such as sickle cell anemia.\textsuperscript{28,29} In this population, autonomic dysfunction has been implicated as a putative risk factor for sudden death.\textsuperscript{28} Alterations in cardiac and autonomic nervous system function are particularly relevant in ESRD, as cardiovascular morbidity and mortality are very common in this population.\textsuperscript{30}

To our knowledge, this is the first report of an association between hemoglobin variability, independent of hemoglobin level and trend, and mortality. A retrospective cohort study of Medicare patients on chronic hemodialysis attempted to explore the association between hemoglobin variability and outcomes, but failed to adequately distinguish between variability, absolute hemoglobin level, and temporal hemoglobin trend.\textsuperscript{15–16,18} In that study, subjects were stratified monthly according to hemoglobin level, and subsequently categorized as having stable hemoglobin level, low-amplitude hemoglobin change, or high-amplitude hemoglobin change.\textsuperscript{25} In this population, autonomic dysfunction has been implicated as a putative risk factor for sudden death.\textsuperscript{28} Alterations in cardiac and autonomic nervous system function are particularly relevant in ESRD, as cardiovascular morbidity and mortality are very common in this population.\textsuperscript{30}

Table 2. Association between hemoglobin exposure parameters and mortality*

<table>
<thead>
<tr>
<th>Exposure</th>
<th>HR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Absolute level of hemoglobin (per g/dl)</td>
<td>0.81 (0.77 to 0.84)</td>
</tr>
<tr>
<td>Temporal trend in hemoglobin (per g/dl per mo)</td>
<td>0.51 (0.44 to 0.59)</td>
</tr>
<tr>
<td>Hemoglobin variability per 0.50 g/dl</td>
<td>1.15 (1.10 to 1.20)</td>
</tr>
<tr>
<td>per 0.75 g/dl</td>
<td>1.24 (1.16 to 1.32)</td>
</tr>
<tr>
<td>per 1.00 g/dl</td>
<td>1.33 (1.22 to 1.45)</td>
</tr>
<tr>
<td>per 1.50 g/dl</td>
<td>1.53 (1.35 to 1.75)</td>
</tr>
</tbody>
</table>

*Adjusted for variables in Table 1 and for one another. Survival analysis (n = 19,150); deaths = 4536.
patients within the 11 to 12.5 g/dl stratum. \(^{15,16}\) Thus, it was unclear if the association between hemoglobin stability and outcomes was attributable to the absence of hemoglobin variability, the absolute hemoglobin level achieved, absence of temporal hemoglobin trend, or some combination of all three.

Numerous studies have examined the association between absolute hemoglobin level and mortality. We observed a 19% reduction in rate of death for each 1-g/dl increase in the level of hemoglobin. This finding is similar in direction and magnitude to findings from previous observational studies. \(^{7–8,31–33}\) It should be noted that prior studies have demonstrated that the survival benefit derived from higher hemoglobin levels is confined to subjects with hemoglobin levels \(\geq 12\) g/dl. \(^{5,8,10,31–33}\) This study did not include a sufficient number of subjects with hemoglobin levels \(>12\) g/dl to permit generalization of its findings to this population. Furthermore, the limited number of subjects in this higher range of hemoglobin prevents us from making inferences regarding the upper limit of hemoglobin treatment targets.

One limitation of this study is the possibility that more comorbid illness led to subsequent higher degrees of Hb-Var, partially explaining the relationship we observed between Hb-Var and mortality. To address this possibility, we sought to conduct analyses among subjects with better health status whose Hb-Var would more likely be the result of treatment protocols rather than variations in health status. To accomplish this, we limited all analyses to subjects with no missing hemoglobin values over the exposure period (hypothesizing that such patients missed fewer outpatient dialysis treatments and were, therefore, healthier). In addition, we performed sensitivity analyses among subgroups of subjects with increasingly restrictive minimum hemoglobin levels (e.g., Hb \(\geq 9.5\) g/dl, \(\geq 10\) g/dl, and \(\geq 10.5\) g/dl), under the assumption that these groups had with a lower prevalence of comorbidities that could function as time-dependent confounders. Two of these three subgroup analyses (Hb \(\geq 9.5\) g/dl and Hb \(\geq 10\) g/dl) yielded results consistent with our primary findings. Analysis of the smallest subgroup (\(\geq 10.5\) g/dl) failed to demonstrate an association between Hb-Var and mortality. It is unclear if this disparity resulted from attenuated statistical power, from residual confounding on the basis of comorbidity in the remaining subgroups, or from a true absence of effect of Hb-Var in this subgroup. Preliminary investigation using formal approaches to control for time-dependent confounding, while beyond the scope of this paper, suggests findings consistent with those presented here. \(^{22}\) As is the case in all observational research, none of these approaches completely eliminates the possibility of unmeasured confounding nor assures the causal nature of the observed associations.

Another potential limitation of our study is that we evaluated a cohort assembled in 1996, when clinical guidelines and practice patterns were substantially different than guidelines today. For example, mean hemoglobin, monthly erythropoietin, and ferritin levels were lower than those reported in more recent cohorts. \(^{1,8}\) Future studies involving cohorts with substantial representation of subjects with hemoglobin levels \(>12\) g/dl will be an important next step in examining the association between Hb-Var and survival.

Although current patterns of Hb-Var may differ from those seen in this historical cohort, evidence suggests that substantial Hb-Var still exists among chronic dialysis patients. \(^{8,15,17–20}\) At least one study documented that, while average levels of hemoglobin increased between 1995 and 2000, the intrapatient SD (a measure of hemoglobin variability) remained constant. \(^{20}\) Furthermore, while changes in practice patterns may affect the degree of Hb-Var seen in dialysis populations, there is no reason to suspect that they would fundamentally alter the relationship between Hb-Var and mortality.

Our study was also limited by the data available to us. In particular, we did not have access to detailed clinical records and were, therefore, only able to include the covariates described in our methods to adjust for confounding. In addition, we had no access to hospitalization data, which prevented us from using such information either as an indication of comorbidity or as a study outcome, per se.

Finally, we studied a large cohort of hemodialysis patients who were all treated within one large US dialysis chain, potentially limiting the generalizability to all chronic hemodialysis patients. Nonetheless, this study of \(>30,000\) hemodialysis patients, who represented 20% of US hemodialysis patients in 1996, included a diverse study group that was likely to be largely reflective of the nation’s dialysis population.

**Conclusion**

We have described a new method of measuring hemoglobin variability that measures variability independent of absolute level and temporal trend in hemoglobin concentration. Greater hemoglobin variability is associated with diminished survival after adjusting for confounders and across multiple modeling strategies. Clinical trials comparing treatment strategies leading to differing degrees of hemoglobin variability will be needed to clarify the true causal nature of the associations.
we have demonstrated. If hemoglobin variability were shown
to have a causal association with mortality, it could become a
novel target whose control among hemodialysis patients may
reduce morbidity and prolong survival.

CONCISE METHODS

Study Population
Adult patients in the FMC database of hemodialysis pa-
tients were eligible for the study if they were alive during one of
two enrollment periods: January 1, 1996, to June 30, 1996; or
July 1, 1996, to December 31, 1996.

Characterizing Hemoglobin Parameters
Hemoglobin variability, absolute hemoglobin level, and
temporal hemoglobin trend were defined over study months 4
through 9. For each subject, a linear regression model of time
on hemoglobin was fit, and Hb-Var was defined as the Res-SD
of these regression models, which is essentially the SD of the
differences between observed hemoglobin values and the re-
gression line (Figure 1a). Absolute value of and temporal
trends in hemoglobin levels were defined as the intercept and
slope of the regression line, respectively. In addition, the aver-
age absolute change in hemoglobin was calculated over the
same exposure windows. This was defined as the average of the
absolute difference between consecutive hemoglobin mea-
surements (Figure 1b).

Outcomes
In the survival analyses, the outcome of interest was death
from any cause. Patients were followed from enrollment until
death or until a censoring event occurred. Censoring events
included transfer from FMC facilities, transplantation, or end
of study on September 30, 1998. Data on cause-specific death
were not available, nor were hospitalization data.

Covariates
Covariates were considered over study months 1 through
3. Demographic variables of interest included gender, race,
and age at enrollment. Comorbid diseases of interest in-
cluded diabetes (adult, juvenile, none) and duration of
ESRD. Laboratory data included serum albumin, aspartate
aminotransferase, bicarbonate, calcium, phosphate, para-
thyroid hormone, iron level, transferrin saturation (TSAT),
ferritin, urea reduction ratio (URR), and Kt/V. [Because
thyroid hormone, iron level, transferrin saturation (TSAT),
ESRD. Laboratory data included serum albumin, aspartate
excluded diabetes (adult, juvenile, none) and duration of
and age at enrollment. Comorbid diseases of interest in-
cluded diabetes (adult, juvenile, none) and duration of
ESRD. Laboratory data included serum albumin, aspartate
aminotransferase, bicarbonate, calcium, phosphate, para-
thyroid hormone, iron level, transferrin saturation (TSAT),
ferritin, urea reduction ratio (URR), and Kt/V. [Because
thyroid hormone, iron level, transferrin saturation (TSAT),
ESRD. Laboratory data included serum albumin, aspartate
excluded diabetes (adult, juvenile, none) and duration of
and age at enrollment. Comorbid diseases of interest in-
cluded diabetes (adult, juvenile, none) and duration of
ESRD. Laboratory data included serum albumin, aspartate
aminotransferase, bicarbonate, calcium, phosphate, para-
thyroid hormone, iron level, transferrin saturation (TSAT),
ferritin, urea reduction ratio (URR), and Kt/V. [Because
thyroid hormone, iron level, transferrin saturation (TSAT),
ESRD. Laboratory data included serum albumin, aspartate
excluded diabetes (adult, juvenile, none) and duration of
and age at enrollment. Comorbid diseases of interest in-
cluded diabetes (adult, juvenile, none) and duration of
ESRD. Laboratory data included serum albumin, aspartate
aminotransferase, bicarbonate, calcium, phosphate, para-
thyroid hormone, iron level, transferrin saturation (TSAT),
ferritin, urea reduction ratio (URR), and Kt/V. [Because
thyroid hormone, iron level, transferrin saturation (TSAT),
ESRD. Laboratory data included serum albumin, aspartate
excluded diabetes (adult, juvenile, none) and duration of
and age at enrollment. Comorbid diseases of interest in-
cluded diabetes (adult, juvenile, none) and duration of
ESRD. Laboratory data included serum albumin, aspartate
aminotransferase, bicarbonate, calcium, phosphate, para-
thyroid hormone, iron level, transferrin saturation (TSAT),
ferritin, urea reduction ratio (URR), and Kt/V. [Because
thyroid hormone, iron level, transferrin saturation (TSAT),
ESRD. Laboratory data included serum albumin, aspartate
excluded diabetes (adult, juvenile, none) and duration of
and age at enrollment. Comorbid diseases of interest in-
cluded diabetes (adult, juvenile, none) and duration of
ESRD. Laboratory data included serum albumin, aspartate
aminotransferase, bicarbonate, calcium, phosphate, para-

Hemoglobin Variation and Mortality
3169
REFERENCES


3. Furuland H, Linde T, Ahlmen J, Christensson A, Strombom U, Daniel-


7. Oftshun N, Labrecque J, Lacson E, Keen M, Lazarus JM: The effects of higher hemoglobin levels on mortality and hospitalization in hemodi-

8. Regidor DL, Kopple JD, Kovesdy CP, Kilpatrick RD, McAllister CJ, Arono-
vitz J, Greenland S, Kalantar-Zadeh K: Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and sur-


10. Besarab A, Bolton WK, Browne JK, Egric JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiv-


17. Berns JS, Elzien H, Lynn RI, Fishbane S, Meisels IS, Deoore PB: Hemoglobin variability in epoetin-treated hemodialysis patients. Kid-

18. Ebben JP, Gibertson DT, Foley RN, Collins AJ: Hemoglobin level va-


21. Mena L, Pintos S, Queipo NV, Aizpurua JA, Maestre G, Subaran T: A reliable index for the prognostic significance of blood pressure vari-

22. Feldman HI, Brunelli SM, Joffe MM, Yang W, Israni RK, Fishbane S: Causal analysis of hemoglobin variability and mortality among hemodi-


25. Habler OP, Messmer KA: The physiology of oxygen transport. Transfu-


27. Meerson FZ, Evesieva ME: Disturbances of the heart structure and function in chronic hemolytic anemia, their compensation with in-


32. Lowrie EG, Curtin RB, LePenn RB, Schatell D: Medical outcomes study working papers. 2007


ACKNOWLEDGEMENTS

R.K.I. was supported by a National Institutes of Health (NIH) individual training grant F32 DK072877–01, and S.M.B. was supported by an NIH institutional training grant for clinical nephrology T32–DK-07785. W.Y. had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

DISCLOSURES

This study was supported by an unrestricted grant from Hoffman-La Roche Company.